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The receptor-type protein tyrosine phosphatase
(RPTP) CD148 is thought to have an inhibitory func-
tion in signaling and proliferation in nonhemato-
poietic cells. However, its role in the immune system
has not been thoroughly studied. Our analysis of
CD148 loss-of-function mice showed that CD148
has a positive regulatory function in B cells and mac-
rophages, similar to the role ofCD45asapositive reg-
ulator of Src family kinases (SFKs). Analysis of CD148
and CD45 doubly deficient B cells and macrophages
revealed hyperphosphorylation of the C-terminal in-
hibitory tyrosineof SFKs accompaniedby substantial
alterations inBandmyeloid lineagedevelopment and
defective immunoreceptor signaling. Because these
findings suggest the C-terminal tyrosine of SFKs is
a common substrate for both CD148 and CD45 phos-
phatases and imply a level of redundancy not previ-
ously appreciated, a reassessment of the function
of CD45 in the B andmyeloid lineages based on prior
data from the CD45-deficient mouse is warranted.
INTRODUCTION
The state of tyrosine phosphorylation is a tightly regulated equilib-
rium, coordinated by the actions of protein tyrosine kinases
(PTKs) and protein tyrosine phosphatases (PTPs). Src family
kinases (SFKs) play essential roles in the initiation of immunore-
ceptor signaling (Iwashima et al., 1994). SFKs have two regulatory
tyrosine phosphorylation sites. Autophosphorylation of the tyro-
sine in the kinase activation loop leads to an increase in catalytic
activity. Dephosphorylation of this tyrosine has an inhibitory effect
and canbe accomplished byseveral PTPs, the best characterized
being PEP (Cloutier and Veillette, 1999). When phosphorylated by
Csk, the second regulatory site in the C-terminal tail of SFKs binds
its own SH2 domain, leading to an autoinhibited ‘‘closed’’ confor-
mation (Sicheri and Kuriyan, 1997). The CD45 RPTP (receptor-like
PTP), highly expressed on hematopoietic cells, is known to
dephosphorylate this tyrosine in SFKs (Hermiston et al., 2003).CD45 (encoded by Ptprc) is critical for the immune system be-
cause both CD45-deficient (Ptprc/) mice (Byth et al., 1996;
Kishihara et al., 1993; Mee et al., 1999) and humans develop se-
vere combined immunodeficiency (SCID) (Kung et al., 2000;
Tchilian et al., 2001). CD45 deficiency affects T lymphocytes
most profoundly. Thymocyte development is severely blocked
at the positive selection stage (Byth et al., 1996; Kishihara
et al., 1993; Mee et al., 1999). In surprising contrast, CD45-defi-
cient B cells develop relatively normally in the bone marrow, al-
though splenic B cell development is partially blocked at transi-
tional stages (Byth et al., 1996; Kishihara et al., 1993). Moreover,
whereas in CD45-deficient T cells TCR-mediated increase in free
intracellular Ca2+ concentration is almost completely abolished
(Koretzky et al., 1991; Mee et al., 1999), in CD45-deficient B cells
it is largely preserved (Benatar et al., 1996; Hermiston et al.,
2005). Nevertheless, CD45-deficient B cells do not proliferate
well in vitro after stimulation with anti-IgM (Benatar et al., 1996;
Byth et al., 1996; Kishihara et al., 1993). However, in vivo re-
sponses to T-dependent and T-independent antigens are almost
normal, with the exception that germinal centers are less persis-
tent, when Ptprc+/+ T cells are supplied (Huntington et al., 2006;
Kong et al., 1995). Collectively, these observations suggest that
CD45 deficiency substantially increases the threshold for TCR
signaling but has diminished or more complex effects on BCR
signaling. Even though SFKs are substrates of CD45, in contrast
to the partial defect in B cell development in CD45-deficient
mice, loss of B cell-specific SFKs blocks B cell development at
the pro-B to pre-B cell transition (Saijo et al., 2003). The different
outcomes from CD45 and SFK deficiencies on B cell develop-
ment suggest that there may be another phosphatase involved.
In the myeloid lineage, no major developmental defects were ob-
served, although myelopoiesis was slightly increased, inPtprc/
mice (Kishihara et al., 1993). Macrophages from these mice
displayed alterations in integrin-mediated adhesion (Roach
et al., 1997). The variable effects of CD45 deficiency in differ-
ent lineages have led to varied interpretations of its func-
tions. One possible explanation for these inconsistencies is
that other mechanisms in B cells and in myeloid cells are
able to compensate for the loss of CD45 in these lineages.
As suggested above, one possibility is another PTP. A candi-
date RPTP is CD148 (encoded by Ptprj). CD148 is expressed in
most leukocyte lineages, including B cells and myeloid cells, but
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Overlapping Function of CD45 and CD148in T cells its expression is induced after activation (Lin et al.,
2004). It differs substantially from CD45, having eight or nine
fibronectin domains in its extracellular domain and a single
(rather than tandem) PTP homology domain. Very limited data
address the function of CD148 in the immune system. In the
Jurkat T cell line, induced expression of CD148 led to selective
dephosphorylation of phospholipase Cg1 (PLCg1) and linker
for activation of T cells (LAT), resulting in downregulation of
TCR-dependent signaling (Baker et al., 2001). Its function in
the B and myeloid lineages is largely uncharacterized. CD148
is also expressed in the cells outside the immune system, includ-
ing epithelial and endothelial cells as well as fibroblasts, where it
was shown to inhibit cell growth and promote differentiation, po-
tentially acting as a tumor suppressor (Balavenkatraman et al.,
2006; Keane et al., 1996; Ruivenkamp et al., 2002; Trapasso
et al., 2000, 2004). It has also been reported to dephosphorylate
the inhibitory C-terminal tyrosine of c-Src in a rat thyroid carci-
noma, leading to increased c-Src activity and cell-substratum
adhesion (Pera et al., 2005).
The replacement of the CD148 PTP domain with GFP in mice
led to early embryonic lethality due to vascular defects, thus pre-
venting any study of the immune system (Takahashi et al., 2003).
Here, we attempted to overcome this difficulty by generating
mice in which the transmembrane (TM) exon ofPtprj is condition-
ally or constitutively deleted. Our constitutively TM exon-defi-
cient mice (PtprjTM/TM) were viable without any gross abnor-
malities. Recently, an independent Ptprj/ mouse showed
similar viability (Trapasso et al., 2006). Our detailed analysis of
the immune system in PtprjTM/TM mice revealed a partial block
in peripheral B cell development, resembling the B cell phenotype
inPtprc/ mice. This raised the possibility that these structurally
distinct RPTPs share overlapping functions. The PtprjTM/TM
and Ptprc/ doubly deficient (DKO) mice had substantial de-
fects in B and myeloid cell lineage development and immunore-
ceptor signaling. Strong hyperphosphorylation of the negative
regulatory C-terminal tyrosine of SFKs in DKO B cells and macro-
phages suggests that failure to dephosphorylate the inhibitory
tyrosine of SFKs leads to the decreased activity of these kinases
in vivo and results in early defects in the signaling pathways me-
diated by BCR and Fc receptors. These studies indicate that the
structurally distinct CD45 and CD148 RPTPs, by dephosphory-
lating the inhibitory tyrosine of SFKs in at least some hematopoi-
etic lineages, have previously unappreciated overlapping posi-
tive regulatory functions.
RESULTS
Generation of PtprjTM/TM Mice
Because the structurally distinct RPTPs CD45 and CD148 (see
Figure S1 available online) are coexpressed in many hematopoi-
etic lineages, we were interested in comparing the conse-
quences of their deficient states. Because of the reported
embryonic lethality of CD148 deficiency in mice, we designed
a lineage-specific inactivation of Ptprj. We inserted loxP recom-
bination sites flanking the TM exon, along with a floxed neo cas-
sette, and isolated mouse embryonic stem cells with the properly
targeted locus (Figure S2). This deletion, if expressed, would re-
sult in a truncated secreted protein. From breeding mice with the
targeted CD148 gene with CMV-Cre mice, we obtained mice not
184 Immunity 28, 183–196, February 2008 ª2008 Elsevier Inc.only with floxed alleles but also mice with a constitutively deleted
transmembrane domain allele PtprjTM/TM. Only mice with the
constitutively deleted allele will be characterized here. The
PtprjTM/TM mice were born at a normal Mendelian frequency
and with a grossly normal life span. As expected, only a secreted
truncated protein representing the extracellular portion of CD148
protein was observed in the serum of PtprjTM/TM mice
(Figure S2). Importantly however, CD148 protein was not
detected on any cells of hematopoietic origin in these mice by ei-
ther immunoblotting or flow cytometry (Figure S2 and data not
shown). Moreover, we have not noted any phenotype in mice
heterozygous for the PtprjTM/+ allele. Thus, the secreted protein
does not appear to bind to hematopoietic cells or cause any
physiologic consequences.
B Cell Development in PtprjTM/TM Mice
Is Partially Impaired
The thymus, spleen, and lymph nodes from the PtprjTM/TM
mice did not exhibit any phenotypic changes throughout T cell
development (Figure 1A, Table S1, and data not shown). There
was no obvious defect in B cell development in the bone marrow
(BM; data not shown). Even though the total T or B cell numbers
in the spleen and lymph node were unchanged, a partial periph-
eral B cell developmental block was observed. Immature B cells
that migrate from the BM to the spleen continue to develop
through transitional stages (T1 and T2), becoming either follicular
mature B cells (CD19+ IgMlo IgDhi) or marginal zone B cells
(CD19+ CD1dhi) (Martin and Kearney, 2000). Spleens from
PtprjTM/TM mice contained more T1 B cells (IgMhi IgDlo) and
fewer follicular mature (FM) B cells (IgMlo IgDhi), implying a partial
block at the T1 stage (Figure 1B and Table S1). Moreover,
PtprjTM/TM mice also had increased splenic marginal zone B
cells (CD19+ CD1dhi) (Figure 1C and Table S1). Skewing toward
the B2 lineage at the expense of the B1 lineage was noted in peri-
toneal lavage B cells (Figure 1D and Table S1). This phenotype in
the PtprjTM/TM B cell lineage was reminiscent of that reported
in Ptprc/ mice (Byth et al., 1996; Hermiston et al., 2005).
Generation of Ptprj and Ptprc Doubly Deficient Mice
The phenotypic similarity of the PtprjTM/TM and Ptprc/
mouse lines lent support to the idea that CD148 and CD45 have
overlapping functions in B cells. We generated PtprjTM/TM
and Ptprc/ doubly deficient mice (PtprjTM/TM/Ptprc/;
DKO), backcrossed for six generations onto the C57BL/6 back-
ground. Due to the infertility of PtprjTM/TM mice, we
have used PtprjTM+/TM/Ptprc+/ or PtprjTM+/TM/Ptprc/ as
breeders and wild-type or single deficient littermates as controls.
PtprjTM+/TM+ and PtprjTM+/TM, or Ptprc+/+ and Ptprc+/ were
used interchangeably because they shared phenotypes. DKO
mice were significantly underweight (60% of WT mice;
Figure 2A) and died prematurely, between 25 to 65 days
(Figure 2B). DKO mice also developed B cell lymphopenia. Total
cell numbers in spleens and lymph nodes were substantially
lower than in the WT, PtprjTM/TM, or Ptprc/ mice (Figures
2C and 2D and data not shown). Before death, all DKO mice de-
veloped a myeloproliferative disorder with extramedullary hema-
topoiesis and distortion of splenic architecture (Figure S3), as well
as extensive myeloid infiltration of the liver (Figure 2E). Scattered
myeloid infiltrates in the lung were also detected (Figure 2F and
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ute to the accelerated mortality, were observed in preterminal
DKO mice. Thus, the phenotypes of the PtprjTM/TM or Ptprc/
mice suggested an additive effect of the loss of function of both
genes and suggested a level of functional redundancy.
Severe B Cell Developmental Block in DKO Mice
To better understand the B cell developmental defect, we ana-
lyzed the B cell compartment of C57BL/6 DKO mice. As previ-
ously reported (Byth et al., 1996; Kishihara et al., 1993) and con-
firmed here, spleens from Ptprc/ mice contain a higher
percentage of B cells due to the T cell developmental block
(Figure 3A). In contrast, spleens from the DKO mice showed
a marked decrease in the percentage as well as the number of
B cells (Figures 3A–3C). Similar to Ptprc/ mice, DKO mice
also have a higher proportion of transitional B cells (IgMhi IgDlo
and IgMhi IgDhi), but the overall B cell number is much lower (Fig-
ures 3A–3C). In the spleens of DKO mice, we also observed an
unusual cell population that expresses CD19, but not IgM nor
IgD. They are slightly bigger than normal B cells (as detected
by forward scatter using flow cytometer) and also express
CD43, CD11b, and Gr1 antigens (data not shown). These cells
may represent an unusual myeloid cell population. We excluded
this population from the B cell gate based on forward and side
scatter intensities during flow cytometer analysis. Further analy-
sis of these cells is in progress.
Decreased B cell numbers in the peripheral organs from DKO
mice indicate that there might be a severe block in early B cell
development in the BM. Indeed, marked decreases in both B
cell percentages as well as absolute numbers were observed
in the DKO BM (Figure 3D and data not shown). CD19+ CD43+
pre-B cell numbers (fraction B and C) were similar in DKO and
WT mice. However, very small numbers of B cells developed fur-
ther to CD19+ CD43 in DKO mice (fraction D) (Figures 3D–3F
and Figure S4). Additionally, there was a substantial decrease
in immature IgM+ IgD and almost no recirculating mature
IgM+ IgD+ B cells were detected in the DKO BM (Figures 3E
and 3F and data not shown).
Accelerated Phenotypes in DKO Mice Backcrossed
onto the C57BL/6 Background
While backcrossing DKO mice, we noted that the B cell pheno-
type, described above, appeared much earlier in DKO mice
that were backcrossed for six generations to C57BL/6 back-
ground when compared to mice of mixed genetic background
(C57BL/6, Balb/c, and 129/Sv). DKO mice that were back-
crossed to C57BL/6 for only two or three generations lived up
to 6 months and were grossly healthy until 2 months of age.
Young mixed-lineage background mice had a mild reduction in
B cell number, similar to that seen in Ptprc/ mice (Figure S5).
Moreover, follicular lymph node B cells were quite homogeneous
across all genotypes, except that both Ptprc/ mice and DKO B
cells expressed higher amounts of IgM compared with WT and
PtprjTM/TM B cells (Figure S5). However, upon aging, these
mice also developed B cell lymphopenia with a profound devel-
opmental block at the pre-B cell stage in the BM, accompanied
by the myeloproliferative disorder (data not shown). This sug-
gested that the severe B cell phenotype and lethality was only
delayed in mixed-lineage mice.Impaired BCR-Mediated Increases in Intracellular Free
Ca2+ in DKO Mice
The attenuated B cell phenotype in less fully backcrossed
DKO mice allowed us to perform biochemical assays using
purified peripheral B cells from these young mixed-lineage
mice (6–8 weeks of age), where B cell development is relatively
normal (Figure S5). We analyzed B cell receptor-mediated eleva-
tion of intracellular free calcium, using purified B cells from lymph
nodes. DKO B cells showed a markedly delayed Ca2+ flux after
BCR crosslinking when compared to WT and singly deficient
mice (Figure 4A). Because there were no marked phenotypic
differences in the lymph node B cell populations across all
genotypes in the mixed-lineage background, the observed delay
in Ca2+ flux is likely to be the result of a defect in BCR-mediated
signaling rather than a consequence of differences in the B cell
populations.
Impaired Src Family Kinase-Dependent Signaling
Pathway in DKO B Cells
To understand the signaling defect, we investigated the BCR-
induced protein tyrosine phosphorylation involved in the initia-
tion of the calcium response. Mixed-background mice were
used because it was not possible to obtain sufficient numbers
of B cells from backcrossed mice. Consistent with the calcium
data, general tyrosine phosphorylation was severely impaired
in DKO B cells (Figure 4B). We noted diminished phosphorylation
and activation of BLNK and PLCg2, proteins upstream of the
calcium response. In addition, activation of the MAP kinase path-
way was also impaired as documented by decreased ERK phos-
phorylation in DKO B cells (Figure 4C and Figure S6), although in
this case lack of CD45 alone was already responsible for a sub-
stantial part of the defect.
The general decrease in tyrosine phosphorylation in DKO B
cells suggested a proximal signaling defect, most likely at the
level of SFKs. The negative regulatory phosphotyrosine of the
SFKs is a primary substrate of CD45. Indeed, we noted in-
creased phosphorylation of the C-terminal inhibitory tyrosine of
the major B cell SFK Lyn (Y507) inPtprc/ mice. This was further
increased in the DKO B cells (Figure 4D and Figure S6). In con-
trast, phosphorylation of the SFK activation loop tyrosine was
not induced in DKO B cells. Collectively, these data suggest
that CD45 and CD148 both dephosphorylate negative regulatory
tyrosines of the SFKs in B cells and, thus, decrease the threshold
for SFK activation.
Defects in BCR-Mediated Signaling in DKO Mice Are
B Cell Intrinsic
Because of the different phenotypes observed on mixed versus
C57BL/6 genetic backgrounds, we tested whether the defect in
BCR-mediated signaling is B cell intrinsic. We performed mixed
BM transplantation by transferring WT together with fully back-
crossed DKO BM cells into lethally irradiated C57BL/6 Ly5.1
(CD45.1+) recipients at a 1:1 ratio. Six to eight weeks after BM
transplantation, we purified lymph node B cells and analyzed
BCR-mediated responses. Although the ratio of DKO to wild-
type B cells in lymph node of the recipient was 30% versus
70%, sufficient numbers of B cells were available for analysis.
After BCR crosslinking, we observed normal Ca2+ increases in
B cells from the WT donor (identified as CD45.2+). In sharp
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Overlapping Function of CD45 and CD148Figure 1. T and B Cell Phenotypes in PtprjTM/TM Mice
(A) Representative FACS analyses of CD4 and CD8 expression on thymocytes from 8-week-old B6 WT and PtprjTM/TM mice to assess stages of thymocyte
development. Numbers in each quadrant represent the percentage of cells in the indicated quadrant.
(B) Splenocytes, pregated on CD19+ CD1dlo to exclude MZ cells, were further analyzed for IgM and IgD to separate into T1 (IgMhi IgDlo) and T2 + FM (follicular
mature) B cells (IgMhi IgDhi for T2 and IgMlo IgDhi for FM).
(C) Splenocytes from the indicated mice were stained with mAb to CD19 and CD1d. Percentages of MZ (CD1dhi) cells in the CD19+ gate are shown.
(D) FACS analysis of peritoneal lavage from 8-week-old B6 WT and PtprjTM/TM mice, stained with mAb to CD19, CD5, and CD23. Percentages of B1b (CD5+
CD23), B1a (CD5 CD23), and B2 (CD5 CD23+) cells in the CD19+ gate are shown. Quantifications of percentages and cell numbers of DP (A), T1 and T2 + FM
(B), MZ (C), B1a and B2 (D) are indicated.
Graphs in this figure show mean ± SEM, three mice per genotype. *p < 0.05. Complete quantification of all subsets is provided in Table S1.
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Overlapping Function of CD45 and CD148Figure 2. DKO Mice on the B6 Background Die Prematurely
(A) Body weight of 4- to 6-week-old mice of the indicated genotypes. Each symbol represents one mouse, and the bar indicates mean.
(B) Mortality curves of mice of the indicated genotypes are shown, where n = 10 for each genotype.
(C and D) Total cell numbers of (C) spleens and (D) lymph nodes from 4- to 6-week-old mice of the indicated genotypes. Symbols represent individual mice, and
bars represent the mean values of each group.
(E) Liver sections (103) from 5-week-old mice of the indicated genotypes stained with H&E. Inserts are 633.
(F) Lung sections (103) from 5-week-old mice of the indicated genotypes stained with H&E.
***p < 0.001.contrast, Ca2+ flux in B cells from DKO donor (CD45.2) was
substantially delayed, similar to that observed in mixed-back-
ground B cells (Figure 5A), despite the fact that B cells from
the DKO donor had slightly higher BCR levels on their surface
than their WT counterparts. This result confirms that the calcium
signaling defect in DKO B cells is B cell intrinsic.
We used such chimeras to test further downstream signaling
by measuring the phosphorylation of ERK kinase using a flow
cytometry-based assay. After BCR crosslinking, most follicularmature B cells from the WT donor (CD45.2+) responded to IgM
stimulation, but only 32% of B cells from DKO donor upregulated
their phospho-ERK level. The majority of the DKO B cells re-
tained basal amounts of ERK phosphorylation. Thus, similar to
calcium signaling, the defect in BCR-mediated ERK activation
is also B cell autonomous. Moreover, because fully backcrossed
mice were used, this study also demonstrates that the observed
signaling defects are independent of the genetic background of
the mouse strains.
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Overlapping Function of CD45 and CD148The B Cell Developmental Defect Is Caused by Both
Intrinsic and Extrinsic Factors
To further test whether the observed developmental block is B
cell autonomous, we used the same chimera as described be-
Figure 4. Impaired BCR-Mediated Signaling
in DKO Mice
(A) Purified lymph node B cells of the indicated
mice were loaded with Fluo3-AM and Fura Red,
and intracellular free-Ca2+ concentrations were
monitored before and after addition of IgM
F(ab0)2 (5 mg/ml). Data are representative of three
independent experiments.
(B) Purified lymph node B cells of all four geno-
types were stimulated with F(ab0)2 fragments of
anti-IgM (5 mg/ml). At the indicated time points,
the cells were lysed in SDS-PAGE sample buffer,
and the lysates were analyzed by immunoblotting
with phosphotyrosine antibody. This is represen-
tative of three independent experiments.
(C) Samples from panel (B) were subjected to im-
munoblotting with phospho-specific antibodies
as indicated. Staining of total Erk served as a load-
ing control.
(D) Samples from panel (B) (the 0 min and 1 min
time points) were stained with site-specific anti-
body against phosphorylated activation loop of
SFKs (Src family P-Y416; this antibody cross-
reacts with multiple SFKs) and against C-terminal
inhibitory phosphotyrosine of Lyn (Lyn P-Y507).
The righthand panels are protein loading controls
in the various genotypes.
See quantification for immunoblots shown in (C)
and (D) in Figure S6. Representative data of two
or three independent experiments are shown in
(C) and (D).
fore and analyzed the chimeras 6 weeks
after transplantation. Surprisingly, in the
chimeric BM, the ratio of WT and DKO
B cells remained close to 1:1 throughout
development in the BM (Figure 5C). In
contrast, as B cells progressed through
further maturation in the spleen, the ratio
became 80% to 20% (WT to DKO) at the
T1 stage, 90% to 10% at the T2 stage,
and was even more skewed in the ma-
ture B cell compartment (Figure 5C).
These results reveal that the B cell intrinsic developmental
block occurs much later at the level of the immature to mature
B cell transition, whereas the defects observed in DKO BM de-
scribed above are caused, at least in part, by extrinsic factors,Figure 3. B Cell Developmental Block in DKO Mice on the B6 Background
(A) Percentages and cell numbers of CD19+ splenocytes from 4- to 6-week-old mice of the indicated genotypes. Graphs show mean ± SEM, four mice per
genotype.
(B) Representative FACS analyses of CD19+ splenocytes stained with mAb to CD19, IgM, and IgD. Percentages of CD19+ B cells, T1 (IgMhi IgDlo) cells, and T2
(IgMhi IgDhi) plus follicular mature (FM) (IgMlo IgDhi) B cells are shown. Data are representative of three independent experiments.
(C) Percentages and absolute numbers of each B cell subset are shown. Graphs show mean ± SEM, three mice per genotype.
(D) Percentages and cell numbers of CD19+ lymphocytes in the BM from 4- to 6-week-old mice of the indicated genotypes. Graphs show mean ± SEM, four mice
per genotype.
(E) Representative FACS analyses of BM cells stained with mAb to CD19 and CD43. Percentages of CD19+ B cells and CD43 or CD43+ in CD19+ gate are shown.
Data are representative of three independent experiments.
(F) Based on the FACS analysis, CD19+ BM B cells were identified as fraction B (CD43+ CD24+ BP1), fraction C (CD43+ CD24+ BP1+), fraction D (CD43 gM
IgD), fraction E (CD43 IgM+ IgD), fraction F (CD43 IgM+ IgD+) (see also Figure S2). Fraction A (B220+, CD19) could not be analyzed due to the lack of the
B220 marker in DKO mice (ND) (Hardy et al., 2000). Cell numbers and percentages of indicated populations were shown in the figure.
Graphs show mean ± SEM, four mice per genotype. *p < 0.05, **p < 0.01, ***p < 0.001.Immunity 28, 183–196, February 2008 ª2008 Elsevier Inc. 189
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Overlapping Function of CD45 and CD148Figure 6. CD148 and CD45 Regulate Fc Receptor-Mediated Phagocytosis and Cytokine Production in BMDMs
(A) BMDMs were incubated with human red blood cells coated with mouse IgG2a mAb. BMDMs with ingested erythrocytes were fixed, labeled with Hoechst, and
quantified using a fluorescent microscope. The phagocytic index was determined as (number of erythrocytes)/(number of nuclei). The phagocytic index of WT
macrophages was then set as 100%. Graph shows mean ± SEM, three mice per genotype. **p < 0.01.
(B and C) BMDMs were stimulated with plate-bound mAb to (B) FcgRII and FcgRIII (2.4G2) or (C) LPS in the presence of brefeldin A for 4 hr. TNF-a production was
detected by intracellular staining with TNF-a-specific antibody. Data are representative of three independent experiments.
(D) BMDMs were stained with 2.4G2 or mouse IgG. Their expression on the BMDMs of the indicated genotypes compared with the negative control (shaded
histogram) are shown. Data shown in this figure are representative of three independent experiments.possibly as a consequence of the dysregulated myeloid com-
partment.
CD148 and CD45 Regulate Fc Receptor-Mediated
Phagocytosis and Cytokine Production
Because both CD45 and CD148 are also expressed in myeloid
cells, we examined whether they play similar roles in this lineage
by studying Fc receptor-mediated pathways ex vivo in BM-de-
rived macrophages (BMDM). Fc receptor-mediated signaling
is a well-defined ITAM-SFK-dependent pathway. Activation of
this pathway results in diverse responses, including phagocyto-
sis, cytokine production, and MAP kinase activation. We first in-
vestigated Fc receptor-mediated phagocytosis using opsonized
human erythrocytes. Fc receptor-mediated phagocytosis was
severely impaired in DKO BMDM (40% of WT) (Figure 6A),
whereas only mild defects were observed in singly deficient
cells. Moreover, Fc receptor-induced tumor necrosis factor-a(TNF-a) production was also severely impaired in DKO BMDMs
(Figure 6B). In contrast, after LPS treatment, TNF-a production
in DKO BMDM was equivalent to WT cells (Figure 6C). We mea-
sured the Fc receptor expression by flow cytometry and found
them to be similar across all genotypes (Figure 6D). The selective
defect in the Fc receptor-mediated signaling in DKO BMDM sug-
gests a requisite role for both CD148 and CD45 in this pathway,
but not in toll-like receptor 4 pathways.
We determined whether Fc receptor signaling by BMDMs had
signaling defects similar to B cells. Indeed, overall tyrosine phos-
phorylation was substantially reduced in DKO BMDMs following
Fc receptor stimulation, whereas no reproducible differences
were observed in singly deficient cells (Figure 7A). Similar results
were obtained with ERK and Akt phosphorylation, where the
maximum response was diminished and substantially delayed
in DKO BMDMs (Figure 7B). Strong hyperphosphorylation of
the Lyn inhibitory tyrosine (Y507) in the DKO cells and mildFigure 5. BCR-Mediated Signaling and B Cell Development in Competitively Reconstituted Chimeras
(A) Cell-autonomous defect in intracellular free-Ca2+ increase. Lethally irradiated recipient mice were reconstituted with BM from DKO and WT control mice. The
donor origins of reconstituted B cells were identified using CD45.2 as a congenic marker: WT B cells were CD45.2+, and DKO B cells were CD45.2. Lymph node
B cells were purified by MACS bead techniques, and the purity was 92.1% (CD19+) for CD45.2+ cells and 97.4% for CD45.2 cells (see Figure S7). Lymph node B
cells were also stained with CD45.2 (upper left) and IgM and IgD (upper right) antibodies. The relative intracellular free-Ca2+ concentrations were monitored before
and after addition of IgM F(ab0)2 (5 mg/ml). Data are representative of three independent experiments.
(B) Cell-autonomous defect in activation of ERK. Purified B cells as in (A) were stimulated with IgM F(ab0)2 (5 mg/ml) or PMA for 2.5 min, fixed, permeabilized, and
then stained with phospho-ERK along with other surface makers. Follicular mature B cells (IgM+ IgD+ CD23+) were separated based on the origin of the donors
(same as in [A]). Phospho-ERK of CD45.2+ (WT origin) and CD45.2 (DKO origin) upon indicated stimulation were overlaid in histograms. Data are representative
of two independent experiments.
(C) B cell development in competitively reconstituted chimera. Cells from BM and spleen were isolated and stained with antibodies as indicated. For BM, CD19+ B
cells were gated to separate CD43+ and CD43. The CD43 cells were further subdivided based on expression of IgM and IgD. For the spleen, CD19+ B cells were
separated based on IgM and IgD expression. The donor origin of each subset was then identified by CD45.2 staining. Percentages of WT and DKO B cells of each
subset in BM and spleen were presented in the overlaid bar graph. Results in (C) are representative of four independent experiments.
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(Figure 7C) was observed in the BMDM. This lent strong support
to the idea that defective SFK activation, caused by hyperphos-
phorylation of the C-terminal inhibitory tyrosine, is responsible
for the diminished Fc receptor-mediated signaling. The func-
tional and signaling defects in DKO BMDMs were independent
of the genetic backgrounds tested (data not shown).
DISCUSSION
We describe new roles for the RPTP CD148 in the regulation of
SFK activity in the immune system. Our studies of PtprjTM/TM
mice showed a phenotype similar to Ptprc/ mice, suggesting
that CD148 is a positive regulator of ITAM-dependent signaling
in the B cell and myeloid lineages. Importantly, analyses of the
signaling pathways in B cells and macrophages from DKO mice
revealed substantial defects not seen in the singly deficient
mice. At the molecular level, DKO B cells displayed impaired
Figure 7. Impaired FcR-Mediated Signaling
in DKO BMDMs
(A) BMDMs of all four genotypes were sensi-
tized with purified mouse IgG (20 mg/ml) and then
stimulated with anti-mouse secondary antibody
(10 mg/ml). Cells were lysed in SDS-PAGE sample
buffer, and the lysates were analyzed by immuno-
blotting with phosphotyrosine antibody (4G10).
Staining of total Erk served as a loading control.
(B) Samples from BMDMs stimulated the same
way as in (A) were subjected to immunoblotting
with phospho-specific antibodies as indicated.
Staining of tubulin represents a loading control.
(C) Samples from panel (B) at the 0 min and 2 min
time points were stained with site-specific anti-
body against the phosphorylated activation loop
of SFKs (Src family P-Y416) and against the
C-terminal inhibitory phosphotyrosine of Lyn
(Lyn P-Y507).
See quantification for immunoblots shown in (B)
and (C) in Figure S6. Data shown in this figure
are representative of three independent experi-
ments.
calcium flux and MAP kinase phosphor-
ylation. Importantly, CD148 and CD45
are both required to optimally dephos-
phorylate the C-terminal negative regu-
latory tyrosine of SFKs, such as Lyn, in
B cells. Very similar defects were also
observed in Fc receptor-mediated acti-
vation and phagocytosis in BMDMs.
These data suggest a high level of re-
dundancy between the two structurally
distinct RPTPs CD148 and CD45 in reg-
ulating SFKs. Moreover, these findings
suggest that a reinterpretation is needed
of the function of CD45 in non-T cell lin-
eages where CD148 is constitutively ex-
pressed and may compensate at least
partially for some of the described phe-
notypes seen in the absence of CD45.
One of the striking features of the DKO mice is their early mor-
tality. We speculate the development of the myeloproliferative
syndrome with liver and lung infiltration likely contributed to their
premature death. Interestingly, the myeloproliferative syndrome
is transplantable with BM and can be observed even in aged chi-
meric mice (data not shown). The animals also develop anemia,
which could contribute to their death. However, the precise
cause of death could be complex because multiple lineages
and pathways may be dysregulated. Further analysis will be
aided by the lineage-specific inactivation of Ptprj.
It is tempting to speculate that the observed defects in SFK
signaling are responsible for the phenotype. Indeed, many fea-
tures of the DKO mice resemble those of mice deficient in differ-
ent combinations of SFKs. A milder myeloproliferative syndrome
was also observed in Lyn-deficient mice (Harder et al., 2001),
suggesting that the reduced activity of SFKs in DKO mice could
explain this phenotype. The myeloproliferative disease in DKO
mice was accompanied by a severe block in early B cell
192 Immunity 28, 183–196, February 2008 ª2008 Elsevier Inc.
Immunity
Overlapping Function of CD45 and CD148development in the C57BL/6 genetic background. However,
a different phenotype was observed in the Lyn singly deficient
mice, which instead display B cell hyperactivity and B cell-medi-
ated autoimmunity leading to severe glomerulonephritis (Hibbs
et al., 1995; Nishizumi et al., 1995). PtprjTM/TM/Ptprc/ defi-
ciency likely affects many SFKs, and so the balance between
the activities of the individual SFKs governs the outcome. Defi-
ciencies in different combinations of SFKs can result in variable
phenotypes, ranging from immunodeficiency (Saijo et al., 2003)
to autoimmunity (Hibbs et al., 1995; Nishizumi et al., 1995) and
leukemogenesis (Marth et al., 1986, 1988). Due to the very lim-
ited number of B cells we obtained from DKO mice, we could
not address the phosphorylation status of the individual SFKs.
However, it is possible that different SFK members are affected
to a varying degree by deficiency in each RPTP. In addition to
SFKs, there may be other substrates of CD148 and CD45 that
contribute to the phenotype we observed in DKO mice.
Our studies of BMDM support a role for CD45 and CD148 in
ITAM receptor-mediated signaling in the myeloid lineage. The
defective Fc receptor-mediated phagocytosis and TNF-a pro-
duction in macrophages derived from the DKO is reminiscent
of SFK and Syk deficiency in macrophages. Previous studies
of Lyn/Hck/Fgr/ mice demonstrated a defect in FcR-me-
diated phagocytosis (Fitzer-Attas et al., 2000). An even more
profound defect in FcR-mediated phagocytosis was observed
in Syk/ mice (Crowley et al., 1997). Thus, it seems likely that
the functions of CD45 and CD148 overlap and converge on
SFKs in ITAM-dependent BCR- and FcR-mediated functions in
B cells and macrophages.
It is intriguing that whereas DKO mice have a severe myelopro-
liferative disease they also develop a B cell developmental block
and impaired BCR and FcR signaling. The myeloproliferative
disease in DKO mice may involve cytokine- and growth factor re-
ceptor-induced pathways in which CD45 and CD148 may play
different roles. Although it is possible that these RPTPs directly
act on cytokine receptor-associated JAK kinases and growth
factor receptor kinases (Irie-Sasaki et al., 2001), our preliminary
data suggest an effect of SFK on inhibitory control of growth
factor receptors.
Strikingly, in mice of a mixed genetic background (C57BL/6,
Balb/c, and 129/Sv), the B cell developmental block in the BM
and the myeloproliferative syndrome were much delayed. Ge-
netic modifiers may contribute to the severity of the disease.
The discordant phenotypes also suggest that the early B cell de-
velopmental block in the DKO mice is not B cell autonomous. A
number of cytokines produced by myeloid cells, such as type I
interferons, can suppress B cell development (Lin et al., 1998).
Relatively normal B cell development in the BM of the young
mixed-lineage mice suggests that lack of CD148 and CD45 per
se is not sufficient to block very early B cell development and
that other factors contribute to the phenotype as the disease
progresses. In addition, data from our competitively reconsti-
tuted chimeras more clearly demonstrated that the very early B
cell developmental block seen in B6 mice is secondary to
some other not fully understood effects, possibly coming from
a dysregulated myeloid compartment. In fact, the only B cell
developmental block that is most likely intrinsic was observed
during immature to mature B cell transition, given the discordant
results obtained between wild-type and DKO B cells in healthychimeric mice at week 6 posttransplantation. It is not clear
how much of this developmental defect is due to the CD45 defi-
ciency alone. Further clarification of this issue will require B cell
lineage-specific conditional DKO mice.
At the molecular level, we observed clear BCR signaling de-
fects in DKO peripheral B cells. In the absence of CD45 and
CD148, the cells maintained a high phosphorylation level of the
C-terminal tyrosine of Lyn, thus keeping the kinase in the inactive
conformation. As a likely consequence, the DKO B cells had im-
paired calcium flux after BCR ligation and failed to activate
PLCg2 and ERK. Importantly, the same defects in calcium flux
and ERK activation in the DKO B cells occurred in competitively
reconstituted chimeras, suggesting that the BCR signaling
defects are in fact B cell intrinsic. Moreover, the signaling defects
observed in the in vitro expanded BMDMs were very similar to
the defects observed in B cells. Finally, our results from DKO B
cells are also consistent with mutants of the DT40 chicken B
cell line, which does not express endogenous CD148 (J.L., un-
published data). CD45-deficient and Lyn-deficient DT40 lines
share very similar BCR-induced calcium signaling defects to
our DKO B cells, exhibiting delayed and decreased peak re-
sponses (Takata et al., 1994; Yanagi et al., 1996). In contrast, cal-
cium flux in Syk-deficient DT40 cells is completely abolished (Ta-
kata et al., 1994). These data suggest that, via the regulation of
SFKs, CD148 and CD45 contribute to the early peak calcium
flux following BCR stimulation, whereas Syk may be responsible
for sustaining the calcium flux after receptor clustering. A similar
model may hold for the partial defects seen in the FcR-mediated
signaling in macrophages. It is also important to stress that most
of the signaling defects we observed in both B cells and macro-
phages were independent of the genetic background.
Although our study demonstrates that in B cells and macro-
phages CD148 and CD45 have similar overlapping functions, it
is not clear whether there is any unique role for CD148 or
CD45 in these lineages. Their very distinct structures suggest
that they may be subject to different regulatory mechanisms.
Previously, CD148 was considered to have an inhibitory role. In
nonhematopoietic cells, CD148 has been reported to act as a tu-
mor suppressor and inhibit proliferation of many different cell
types predominantly of epithelial origin, most likely via dephos-
phorylation of different growth factor receptors (Balavenkatra-
man et al., 2006; Jandt et al., 2003; Keane et al., 1996; Kovalenko
et al., 2000; Lesueur et al., 2005; Palka et al., 2003; Ruivenkamp
et al., 2002, 2003; Trapasso et al., 2000, 2004). It is possible that
CD148 plays different roles depending on cell type and redun-
dancy with other proteins. The overall phenotype reflects a net
effect on the entire spectrum of available substrates that may
be different in distinct cell types. It is possible that in B cells
and myeloid cells the positive regulatory role of CD148 on Src-ki-
nases prevails. Indeed, a study on rat thyroid carcinoma showed
that overexpression of CD148 led to specific dephosphorylation
of the C-terminal regulatory phosphotyrosine of c-Src that led to
increased substratum adhesion (Pera et al., 2005).
Our study identifies CD148 as an important regulator of SFKs
and suggests that it does so in concert with CD45 in at least
some hematopoietic lineages. In B cells and macrophages,
CD148 dephosphorylates the negative regulatory phosphotyro-
sine of SFKs and therefore together with CD45 helps to set the
threshold for SFK activation and, hence, the threshold for the
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portant components of many other signaling pathways in hema-
topoietic cells, it is reasonable to expect that CD148 may have
complex effects at multiple levels of immune cell regulation. Fu-
ture studies of CD148 may provide not only deeper insights into
the function of this RPTP itself but also of SFKs and immune cell
regulation in general.
EXPERIMENTAL PROCEDURES
Generation of PtprjTM/TM Mice
Detailed methods for the generation of PtprjTM/TM mice are described in
Figure S2. PtprjTM/TM mice were backcrossed to C57BL/6 mice for at least
six generations. To generate DKO mice, PtprjTM/TM mice were crossed to
Ptprc/ mice (exon 6 disruption, in C57BL/6 strain, obtained from E. Brown,
UCSF). All animals used in the experiments were at 6–10 weeks of age. All an-
imals were housed in a specific pathogen-free facility at UCSF and were
treated according to protocols that were approved by university animal care
ethics and veterinary committees and are in accordance with NIH guidelines.
Antibodies and Reagents
Antibodies to murine CD1d, CD3, CD4, CD5, CD8, CD19, CD21, CD23, CD24,
CD43, CD45.1, CD45.2, BP-1, Gr1, IgM, IgD, Mac1, TNF-a conjugated to
FITC, PE, PerCP, APC, APC-Alexa750, or Pacific Blue were from BD Biosci-
ences. Anti-phosphotyrosine antibody 4G10 was from Upstate Biotechnology.
Antibodies to phospho-BLNK (Tyr96), phospho-PLCg2 (Tyr1217), phospho-
Erk (Thr202/Tyr204), phospho-Src family (Tyr416), phospho-Lyn (Tyr507),
and phospho-Akt (Ser473) were purchased from Cell Signaling Technology.
Goat anti-mouse IgG, goat anti-mouse IgM [F(ab0)2 fragments], and purified
mouse IgG were from Jackson Immunoresearch. Mouse IgG2a antibody to hu-
man CD59 (MEM-43) was kindly provided by V. Horejsi (Institute of Molecular
Genetics, Prague, Czech Republic). Erk1 and Erk2 antibodies were from Santa
Cruz Biotechnology. Tubulin antibody was obtained from Sigma.
Isolation and Activation of Primary B Cells
Mouse lymph node B cells were purified by negative selection with CD11b-
and CD43-conjugated magnetic beads (Miltenyi Biotec). Purified B cells
were resuspended in serum-free RPMI (108 per ml) and activated by 5 mg/ml
goat anti-mouse IgM [F(ab0 )2] (Jackson Immunoresearch). Aliquots of 5 3 10
6
cells were transferred directly to SDS-PAGE sample buffer.
Flow Cytometry
Single-cell suspensions were prepared from peritoneal lavage, lymph nodes,
spleen, and BM. Fc receptors were blocked with rat anti-CD16/CD32
(2.4G2). 106 cells were stained with the indicated antibodies and analyzed
on a FACSCalibur (BD Biosciences) or CyAn ADP (Dako) flow cytometers.
Intracellular Phospho-ERK Staining
Spleen cells were stained with FITC-conjugated mouse IgM [F(ab)0] monomer,
then stimulated with 5 mg/ml goat anti-mouse IgM [F(ab0)2] (Jackson Immunor-
esearch) or PMA for 2.5 min and fixed with 2% paraformaldehyde. Cells were
permeabilized with 100% ice-cold methanol, stained with anti-phospho-ERK
(Cell Signaling Technology), IgD, and CD23 antibody and then analyzed on
the CyAn ADP (Dako).
Calcium Flux
Mouse lymph node B cells were loaded with a mixture of Fluo-3 (2 mg/ml) and
Fura Red (4 mg/ml) for 30 min at 37C in complete culture media. Cells were
analyzed by flow cytometry (FACS Calibur) at 37C and activated by 5 mg/ml
F(ab0)2 goat anti-mouse IgM. Calcium flux was monitored as a ratio between
Fluo-3 and Fura Red fluorescence. Purified lymph node B cells derived from
adoptively transferred BMs were loaded with Fluo-3 only and labeled with
APC-conjugated CD45 antibody to distinguish wild-type and DKO cells,
and the concentration of intracellular free calcium was measured as Fluo-3
fluorescence.
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BMDMs were prepared by culturing mouse BM cells in BMDM media (RPMI-
1640 with 10% FCS and 10% culture supernatant from L929 CMG cells pro-
ducing M-CSF). Macrophages were used for experiments between days 7 and
9 of culture. For immunoblot analysis, BMDMs were plated in 6-well tissue cul-
ture plates (Costar) in BMDM media, 106 per well. The next day, the cells were
washed with serum-free RPMI and incubated with 20 mg/ml purified mouse
IgG (Jackson Immunoresearch) for 30 min at 4C. Cells were washed, incu-
bated for 15 min at 37C, and then activated with goat anti-mouse antibody
(Jackson Immunoresearch), 10 mg/ml. The stimulation was stopped by adding
SDS-PAGE sample buffer. Samples were analyzed by SDS-polyacrylamide
gel electrophoresis (PAGE) and immunoblotting. To assess TNF-a production,
24-well non-tissue culture plates were coated with DOTAP (1 mg/ml) (Sigma
D-6182) for 10 min followed by incubation with anti-FcgR antibody (2.4G2),
10 mg/ml, overnight at 4C. BMDMs (2 3 105) were added to each well to-
gether with brefeldin A, 10 mg/ml, and incubated for 4 hr at 37C. For LPS stim-
ulation, LPS (List Biological Laboratories Inc. #304) was directly added to the
cells together with brefeldin A, 10 mg/ml. Cells were then harvested and
stained intracellularly with TNF-a Ab and analyzed by flow cytometry.
Phagocytosis Assay
Human erythrocytes were prepared from human blood from healthy donors
over Histopaque 1119 (Sigma) and labeled with FITC (0.1 mg/ml in PBS, over-
night at 4C) followed by opsonization with 10 mg/ml mouse IgG2a antibody
against human CD59 (MEM-43, V. Horejsi). BMDMs were plated on sterile
glass coverslips in a 6-well plate, 5 3 105 per well, and cultured overnight at
37C. Then BMDMs were incubated with 7 3 106 opsonized human erythro-
cytes for 30 min at 37C, washed twice with PBS, and noninternalized erythro-
cytes were lysed in a hypotonic ACK buffer. The macrophages were fixed and
labeled with Hoechst (1 mg/ml). Slides were analyzed on a fluorescent micro-
scope (Marianas Turn-Key system using Slidebook software, Intelligent Imag-
ing Innovations). The phagocytic index represents the number of erythrocytes
per number of nuclei and normalized as a percentage of the phagocytic index
of wild-type BMDMs.
Adoptive Transfer
BM chimeras were generated by transfer of wild-type and DKO BM into lethally
irradiated Ly5.1 recipients at a 1:1 ratio. Recipients were sacrificed 6–8 weeks
later.
Statistical Methods
Statistical analyses were performed with Prism4 (GraphPad Software). Stu-
dent t test analysis was used to calculate the p value. Error bars represent
standard errors of the mean.
Supplemental Data
The Supplemental Data for this article, including figures and a table, can be
found online at http://www.immunity.com/cgi/content/full/28/2/183/DC1/.
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